Cochlear Ltd
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products. It also provides cochlear nucleus systems, including Nucleus sound processors, smart bimodal hearing solution, and Nucleus implants; cochlear Baha systems comprising Baha 6 max sound processor… Read more
Market Cap & Net Worth: Cochlear Ltd (COH)
Cochlear Ltd (AU:COH) has a market capitalization of $7.01 Billion (AU$11.32 Billion) as of March 18, 2026. Listed on the AU stock exchange, this Australia-based company holds position #2183 globally and #13 in its home market, demonstrating a -3.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cochlear Ltd's stock price AU$173.07 by its total outstanding shares 65398462 (65.40 Million).
Cochlear Ltd Market Cap History: 2015 to 2026
Cochlear Ltd's market capitalization history from 2015 to 2026. Data shows growth from $3.39 Billion to $7.01 Billion (8.51% CAGR).
Index Memberships
Cochlear Ltd is a constituent of 8 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
S&P/ASX 50
AFLI
|
$279.75 Billion | 2.50% | #10 of 50 |
|
Australia All Ordinaries
AORD
|
$319.42 Billion | 2.19% | #9 of 495 |
|
S&P/ASX 100
ATOI
|
$335.58 Billion | 2.08% | #10 of 100 |
|
S&P/ASX All Australian 50
AXAF
|
$180.90 Billion | 3.86% | #9 of 50 |
|
S&P/ASX All Australian 200
AXAT
|
$279.96 Billion | 2.49% | #9 of 200 |
|
S&P/ASX 200
AXJO
|
$265.75 Billion | 2.63% | #9 of 200 |
|
S&P/ASX 200 Accumulated
AXJOA
|
$265.75 Billion | 2.63% | #9 of 200 |
|
S&P/ASX 300
AXKO
|
$408.55 Billion | 1.71% | #10 of 300 |
Weight: Cochlear Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cochlear Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cochlear Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.50x
Cochlear Ltd's market cap is 4.50 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
27.14x
Cochlear Ltd's market cap is 27.14 times its annual earnings
1.97x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.43 Billion | $1.13 Billion | $188.92 Million | 3.92x | 23.45x |
| 2017 | $6.31 Billion | $1.25 Billion | $223.62 Million | 5.03x | 28.20x |
| 2018 | $6.49 Billion | $1.36 Billion | $245.80 Million | 4.76x | 26.40x |
| 2019 | $8.55 Billion | $1.43 Billion | $276.70 Million | 5.99x | 30.89x |
| 2020 | $7.26 Billion | $1.35 Billion | -$238.30 Million | 5.37x | N/A |
| 2021 | $8.40 Billion | $1.49 Billion | $326.50 Million | 5.62x | 25.72x |
| 2022 | $8.05 Billion | $1.64 Billion | $289.10 Million | 4.90x | 27.83x |
| 2023 | $11.93 Billion | $1.94 Billion | $300.60 Million | 6.16x | 39.70x |
| 2024 | $11.74 Billion | $2.24 Billion | $356.80 Million | 5.25x | 32.90x |
| 2025 | $10.56 Billion | $2.34 Billion | $388.90 Million | 4.50x | 27.14x |
Competitor Companies of COH by Market Capitalization
Companies near Cochlear Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Cochlear Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #79 globally with a market cap of $190.05 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #153 globally with a market cap of $121.18 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #169 globally with a market cap of $112.92 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #191 globally with a market cap of $103.18 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #79 | Abbott Laboratories | NYSE:ABT | $190.05 Billion | $109.95 |
| #153 | Stryker Corporation | NYSE:SYK | $121.18 Billion | $349.56 |
| #169 | Medtronic PLC | NYSE:MDT | $112.92 Billion | $88.24 |
| #191 | Boston Scientific Corp | NYSE:BSX | $103.18 Billion | $69.79 |
Cochlear Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Cochlear Ltd's market cap moved from $3.39 Billion to $ 7.01 Billion, with a yearly change of 8.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$7.01 Billion | -33.60% |
| 2025 | AU$10.56 Billion | -10.08% |
| 2024 | AU$11.74 Billion | -1.64% |
| 2023 | AU$11.93 Billion | +48.33% |
| 2022 | AU$8.05 Billion | -4.21% |
| 2021 | AU$8.40 Billion | +15.66% |
| 2020 | AU$7.26 Billion | -15.05% |
| 2019 | AU$8.55 Billion | +31.71% |
| 2018 | AU$6.49 Billion | +2.91% |
| 2017 | AU$6.31 Billion | +42.35% |
| 2016 | AU$4.43 Billion | +30.72% |
| 2015 | AU$3.39 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Cochlear Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.01 Billion USD |
| MoneyControl | $7.01 Billion USD |
| MarketWatch | $7.01 Billion USD |
| marketcap.company | $7.01 Billion USD |
| Reuters | $7.01 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.